Skip to content

IMMUNE PHARMACEUTICALS INC

CIK 0001208261

← back to feed
Revenue (TTM)
$0
Q3 Nov 2018
Net Income (TTM)
−$19.28M
+45.2% YoY Q3 Nov 2018
EPS Diluted (TTM)
—
Q3 Nov 2018
Gross Margin
—
Q3 Nov 2018
Operating Margin
—
Q3 Nov 2018
Net Margin
—
Q3 Nov 2018
Free Cash Flow (TTM)
−$12.38M
Q3 Nov 2018
Cash
$76K
Q3 Nov 2018
Total Debt
$870K
Q3 Nov 2018
Shares Outstanding
49.31M sh
Q3 Nov 2018

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings